Related Experiment Video
Updated: Nov 9, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
A potentially effective drug for patients with recurrent glioma: sermorelin
Yuanhao Chang1, Ruoyu Huang1, You Zhai1
1Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Background:
Treatment insensitivity is the main cause of glioma. This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data.
Methods:
A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study. There were 325 patients in the discovery cohort, including 229 primary patients and 92 recurrent patients. There were 693 patients in the validation cohort, including 422 primary patients and 271 relapsed patients. Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening. The analysis and drawing in this study were mainly based on R language.
Results:
After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin. Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status. GO and KEGG analyses found that sermorelin may inhibit tumor cell proliferation by cell cycle blocking. Moreover, sermorelin was also related to the immune system process and negatively regulated immune checkpoints and M0 macrophages. Lastly, the Kaplan-Meier method showed the patient's benefit from sermorelin was independent of postoperative adjuvant treatment.
Conclusions:
Recurrent glioma patients are sensitive to sermorelin and it makes effect through glioma cells proliferation inhibiting and immune response enhancing.
Insights
Recurrent glioma patients show sensitivity to sermorelin, a drug that inhibits tumor cell proliferation and enhances immune response. This finding offers a new therapeutic avenue for treatment-insensitive gliomas.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Treatment insensitivity is a primary challenge in glioma management.
- Transcriptomic data analysis is crucial for identifying effective therapies for recurrent gliomas.
Purpose of the Study:
- To screen for effective drugs for recurrent gliomas using transcriptomic data.
- To identify patient subgroups most likely to benefit from targeted therapies.
Main Methods:
- Utilized transcriptome sequencing and clinical data from 1,018 glioma patients.
- Employed Drug Resistant Scores (DRS) for high-throughput screening of 4,865 drugs.
- Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.
Main Results:
- Sermorelin demonstrated significant sensitivity in recurrent glioma patients.
- Optimal efficacy observed in high-grade, IDH-wildtype, and 1p/19q non-codeleted recurrent gliomas.
- Sermorelin inhibits proliferation via cell cycle blockade and modulates immune responses, including immune checkpoints and M0 macrophages.
Conclusions:
- Recurrent gliomas exhibit sensitivity to sermorelin.
- Sermorelin's efficacy is linked to inhibiting glioma cell proliferation and enhancing immune responses.
- Patient benefit from sermorelin is independent of postoperative adjuvant treatment.
